Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Aramchol meglumine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,133Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galmed Reports Significant AM-001 Study Results For Aramchol
    Galmed Reports Significant AM-001 Study Results For Aramchol

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-meaningful-top-line-results-from-am-001-study-of-aramchol-meglumine-302618567.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share
    galmed identifies biomarker for aramchol, expanding beyond NASH
    galmed identifies biomarker for aramchol, expanding beyond NASH

    27 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-identifies-proprietary-biomarker-signature-for-aramchol-unlocking-multi-billion-dollar-expansion-potential-beyond-nash-302465691.html

    PR NEWSWIRE
    27 May 2025
    Share Share
    Galmed Reports Anti-Fibrotic Effects of Aramchol in PSC Models
    Galmed Reports Anti-Fibrotic Effects of Aramchol in PSC Models

    13 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-significant-anti-fibrotic-effects-of-aramchol-in-psc-models-302453710.html

    PR NEWSWIRE
    13 May 2025
    Share Share
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-first-time-results-in-oncology-studies-aramchol-significantly-enhances-bayers-regorafenib-effect-in-gi-cancer-models-302447161.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    Galmed Pharmaceuticals & VCU Collab on Drug Resistance GI Cancer
    Galmed Pharmaceuticals & VCU Collab on Drug Resistance GI Cancer

    17 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-launches-vcu-collaboration-to-tackle-drug-resistance-in-gi-cancers-302431484.html

    PR NEWSWIRE
    17 Apr 2025
    Share Share
    Galmed Reveals New Blood Markers for Aramchol, Advanced SCD1 Inhi
    Galmed Reveals New Blood Markers for Aramchol, Advanced SCD1 Inhi

    15 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-unveils-novel-pharmacodynamic-blood-markers-for-aramchol-the-most-clinically-advanced-scd1-inhibitor-302428834.html

    PR NEWSWIRE
    15 Apr 2025
    Share Share